410 results about "Atrophy" patented technology

A method based on a multi-task learning model comprises the following steps: acquiring and processing histopathological image data of gastritis through a data preparation and preprocessing step; feature extraction is performed by using a self-supervised learning pre-trained model, and image blocks are coded into high-dimensional feature vectors; and constructing a multi-task learning model, learning feature representation through a full connection layer module and an attention layer module, and outputting a classification result of each task. And carrying out model training and optimization by using an optimizer, adding multitask loss through a loss function, and dynamically adjusting the model performance. The trained model can automatically detect and grade gastritis, atrophy, acute activity, intestinal metaplasia and other pathological indexes, outputs a standardized evaluation result, and assists in pathological diagnosis. According to the method, a multi-task deep learning framework based on self-supervised learning pre-training is constructed, a traditional single-task modeling mode is broken through, deep learning framework design is driven through pathological index association, and accuracy and clinical practicability of non-neoplastic disease assessment of the stomach are remarkably improved.

The invention discloses an optic disk atrophy arc image segmentation method based on full supervision, and particularly relates to the technical field of medical equipment, and the method comprises the following steps: S1, multi-scale feature extraction, S2, local-global feature enhancement, S3, adaptive feature fusion, S4, gradient flow optimization, S5, mixing of a loss function, and S6, data enhancement and generalization optimization. According to the method, the long-range dependence of the optic disk and the atrophic arc is globally modeled through the PVTv2 encoder, the detail segmentation precision of the optic disk atrophic arc at the blood vessel crossing and fuzzy boundary is remarkably improved in combination with the multi-scale attention and dilated convolution of the feature enhancement module, cross-level feature fusion is realized with linear complexity based on the Mama decoder, and the accuracy of feature fusion is improved. Efficiency and structure coherence are considered; the weight is balanced by the mixed loss function, and early lesion missing detection is reduced; a data enhancement and residual module enhances the generalization ability of the model, and a high-precision and efficient quantitative analysis tool is integrally provided for early screening of blind eye diseases such as pathological myopia and glaucoma.

The invention discloses an ultrasound-based diabetic renal lesion risk detection method and system, and relates to the technical field of ultrasonic detection.According to the system, through continuous scanning of a two-dimensional ultrasonic probe, an elastic imaging probe and a Doppler probe, the shape, structure, blood flow characteristics and cortex images of the kidney are obtained; an image processing technology is adopted for preprocessing, space registration and fusion, and a kidney area is automatically segmented; according to the extracted kidney tissue characteristics, calculating an atrophy risk coefficient and a fibrosis risk coefficient, and comparing with a standard threshold value to evaluate the kidney lesion risk; calculating a comprehensive risk coefficient in combination with blood glucose, urine protein and diet data, and evaluating diet influence risks; a renal lesion risk assessment model is constructed by using a convolutional neural network and a machine learning algorithm, a renal lesion prediction function is generated, and the system can accurately assess the renal lesion risk of a diabetic patient and provide early diagnosis and personalized treatment suggestions.

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and / or pulmonary hypertension.

The invention provides an Alzheimer's disease virtual injury judgment method based on a brain dynamics model, and the method comprises the steps: S1, obtaining a structural magnetic resonance image and a functional magnetic resonance image of a subject, and carrying out the preprocessing, and obtaining the preprocessed data; s2, calculating topological characteristic indexes of the structural network; s3, drawing a required topological feature profile map; s4, clustering is carried out on the topological feature profile map; s5, constructing a whole brain dynamic model for each subject; s6, constructing a node disturbance model of each subject, and analyzing a relationship among a structural network topology characteristic index, a cortical hierarchy gradient index and a whole brain dynamic index; s7, according to the cortex thickness and the cortex volume of the subject, in combination with the whole brain dynamics model, judging the influence of local brain region atrophy on whole brain metastable state dynamics; and S8, judging the influence of white matter fiber bundle connection disconnection on the whole brain metastable state dynamics. The invention provides a brain network dynamics model modeling method for different structure damage effects.

The invention relates to the technical field of artificial intelligence, and provides a gastric cancer risk quantitative scoring method, system and equipment based on artificial intelligence, and the method comprises the steps: recognizing the image type of each image frame in alimentary canal endoscope image data; for the electronic dyeing image frame, identifying a part contour region and an intestinal contour region of the feature part in the image frame, determining an intestinal epithelial metaplasia grading category of the feature part according to an area proportion of the intestinal contour region in the part contour region, and performing electronic dyeing intestinal scoring on the image data; for the white light image frame, gastroscope part types included in the image frame and focus area types of all gastroscope parts are recognized; performing atrophy scoring on the image data according to the position distribution of the focus area of the atrophy type; performing table state scoring on the image data according to whether the plica enlargement, nodular gastritis and diffuse redness focus areas exist or not; and realizing gastric cancer risk quantitative scoring according to the electronic staining intestinal scoring, the atrophy scoring and the epistatic state scoring.

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (such as anemia).

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and / or cardiometabolic disease, bone damage, and / or low red blood cell levels (such as anemia).

The invention discloses a traditional Chinese medicine composition for treating sarcopenia, the traditional Chinese medicine composition is prepared from six medicines of sugared ginseng, cistanche, rhizoma polygonati, poria cocos, gastrodia elata and bighead atractylodes rhizome through compatibility, the traditional Chinese medicine composition takes spleen strengthening, qi supplementing, kidney tonifying and essence replenishing as the treatment rule, syndrome differentiation treatment is carried out aiming at the spleen and kidney deficiency pathogenesis of sarcopenia, multi-target intervention on sarcopenia is achieved, and the traditional Chinese medicine composition has the advantages that the curative effect is good; the traditional Chinese medicine composition not only can quickly improve muscle strength and endurance functions, but also can continuously promote muscle mass reconstruction, and has dual effects of atrophy resistance and fibrosis resistance, and animal experiment results show that the traditional Chinese medicine composition has a remarkable curative effect on liver and kidney deficiency type sarcopenia.

The invention discloses a preparation method of omasycine tosylate for injection, and belongs to the technical field of pharmaceutical preparations. The preparation method of the olmacycline tosylate for injection comprises the following steps: filtering a mixture solution containing the olmacycline tosylate, the cane sugar, the pH regulator and the water for injection, filling and sealing, and freeze-drying to obtain the olmacycline tosylate for injection. According to the preparation method, the problem that in the prior art, intermediate product liquid medicine is not completely dissolved is solved, the prepared freeze-dried product is free of the problems of atrophy, collapse, bottom sticking, layering and the like, the preparation method is simple, easy to operate and reliable, the obtained freeze-dried product is low in moisture content and impurity content, the stability is improved, and the product quality is guaranteed.

The present invention discloses the use of extracellular vesicles derived from oligodendrocytes carrying FTH1 in differentiating between multiple system atrophy and Parkinson's disease, belonging to the field of biomedical technology. The present invention utilizes fluorescently labeled CNPase antibodies and FTH1 antibodies to accurately detect extracellular vesicles derived from oligodendrocytes carrying FTH1 in plasma. By detecting the concentration of extracellular vesicles derived from oligodendrocytes carrying FTH1 (FTH1-positive) in plasma, it is possible to accurately distinguish between MSA patients, PD patients, and healthy individuals. This provides a highly effective biomarker for MSA diagnosis, improves the ability to diagnose MSA early and differentiate between MSA and PD, and effectively addresses the complexity and low sensitivity issues faced by traditional diagnostic methods.

The invention relates to the technical field of small molecule medicines, in particular to a medicine for improving chronic atrophic gastritis and application of the medicine. The invention aims to provide a compound, a pharmaceutical composition containing the compound and application of the compound, the 9, 13-substituted berberine derivative has a good improvement effect on CAG, and further research and observation of the compound on treatment of CAG gastric mucosa gland epithelial cell atrophy, gastric mucosa thinning, gastric mucosa epithelial cell atrophy, gastric mucosa hyperplasia, gastric mucosa epithelial cell atrophy and gastric mucosa hyperplasia. The 9, 13-substituted berberine derivative disclosed by the invention can be used for preventing and / or treating CAG (chorionic gonadotrophin) by virtue of the inhibition effects on infiltration adhesion of a large number of neutrophils and lymphocytes, inflammatory factors and the like.

The invention discloses a traditional Chinese medicine preparation for treating multi-system atrophic upright hypotension and a preparation method. The traditional Chinese medicine preparation is prepared from the following raw materials: ginseng, astragalus membranaceus, antler, roasted ephedra, rehmannia, radix ophiopogonis, radix paeoniae alba, rhizoma cimicifugae and pericarpium citri reticulatae viride. The traditional Chinese medicine composition has the effects of tonifying qi, warming yang, nourishing blood and yin and ascending and descending qi function, and emphasizes the effect of ascending and descending qi function in blood pressure regulation by perfecting the etiology and pathogenesis of MSA erect hypotension; the pathogenesis of the MSA erect hypotension is mainly viscera asthenia and qi and blood ascending and descending disorder, so that the treatment effect is achieved by ascending yang and nourishing yin.

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The invention discloses a multi-task autoimmune gastritis gastroscope image classification method and device and a medium, and the method comprises the steps: obtaining a plurality of gastroscope images of a patient, and carrying out the registration of all gastroscope images, and obtaining a similarity matrix; according to the similarity matrix, the gastroscope images are clustered, so that the gastroscope images are grouped, and a plurality of gastroscope image groups are obtained; respectively inputting each gastroscope image group into a first classification network and a second classification network to obtain a first classification label and a second classification label, and obtaining a result pair (the first classification label and the second classification label) corresponding to the current gastroscope image group; wherein the first classification label comprises gastric anatomical parts including the stomach fundus, the stomach body and the gastric antrum, and the second classification label comprises lesion conditions including normal and atrophy. According to the method, the requirements for a large receptive field, local fine-grained information and inductive bias in anatomical region classification and lesion condition classification are considered, and gastroscope images are accurately classified.

The invention discloses a YOLO deep learning-based medial temporal lobe atrophy grade automatic scoring system. The system comprises a coronal section screening module, an improved YOLOv8 model construction module, an optimal coronal section automatic selection module and a medial temporal lobe atrophy detection and automatic scoring module. The invention provides an automatic MTA scoring technology which gives consideration to accuracy, universality and operation convenience. By using a lightweight deep learning YOLO target detection framework and combining with a proper loss function, the calculation overhead is reduced while the algorithm performance is ensured, and by combining with a friendly front-end interaction interface, the efficiency and accuracy of clinical MTA scoring are improved. The automatic scoring system for the medial temporal lobe atrophy is efficient, accurate and consistent, has remarkable clinical application value and popularization prospects, and is expected to play an important role in early diagnosis and monitoring of neurodegenerative diseases such as Alzheimer's disease.

To provide novel monoclonal anti-α-synuclein antibodies.SOLUTION: Disclosed is an antibody that can bind to the toxic α-synuclein fragment 1 to 119 / 122 and neutralize this truncated form of α-synuclein. The antibody can be used to treat synucleinopathies such as Parkinson's disease (including idiopathic and hereditary Parkinson's disease), diffuse Lewy body disease (DLBD), Lewy body variant Alzheimer's disease (LBV), combined Alzheimer's and Parkinson's disease, pure autonomic failure, and multiple system atrophy.SELECTED DRAWING: None

The invention discloses ultrasonic response type hydrogel as well as a preparation method and application thereof. According to the ultrasonic response type hydrogel preparation, an ultrasonic triggering threshold value is reduced to 1W / cm < 2 > by utilizing a synergistic anti-inflammatory mechanism that the Mxene enzyme activity is enhanced by ultrasound, muscle heat tolerance is met, and heat loss is avoided. And under the ultrasonic activation condition, the activity of various enzymes of Mxene is increased. Besides, according to the anti-aging multi-mechanism collaborative design, aiming at inflammation-aging-atrophy vicious circle of sarcopenia, ultrasonic enhanced enzyme activity, anti-inflammation, anti-oxidation and anti-aging treatment of sarcopenia is realized for the first time.

The invention discloses application of FTH1-carrying oligodendrocyte-derived extracellular vesicles in identification of multi-system atrophy and Parkinson's disease, and belongs to the technical field of biomedicine. According to the present invention, the fluorescence labeling CNPase antibody and the FTH1 antibody are adopted to accurately detect the oligodendroglia-derived extracellular vesicles carrying FTH1 in the plasma, and the concentration of the oligodendroglia-derived extracellular vesicles carrying FTH1 (FTH1 positive) in the plasma is detected so as to accurately distinguish MSA patients, PD patients and healthy people, such that the efficient MSA diagnosis biomarker is provided, and the application prospect is broad. The MSA early diagnosis capability and the MSA and PD identification capability are improved, and the problems of complexity and low sensitivity of a traditional diagnosis method are effectively solved.

The present invention relates to activin receptor IIA type variants and methods of use thereof. The present invention features a polypeptide comprising an extracellular ActRIIa variant. In some embodiments, the polypeptides of the present invention comprise an extracellular ActRIIa variant fused to an Fc domain monomer or part. The invention also features the treatment of diseases and conditions involving muscle weakness and atrophy using said polypeptides, such as Duchenne muscular dystrophy, facial shoulder brachial muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; the present invention relates to pharmaceutical compositions and methods for treating a metabolic disease, such as obesity, type 1 diabetes mellitus or type 2 diabetes mellitus.

Provided herein are ultrasound imaging systems and methods of estimating a size / volume of an anatomical feature of a subject using an ultrasound imaging system. As described, the systems and methods combines automatic image segmentation through artificial intelligence with inertial measurement unit data to improve the accuracy of organ and tissue volume measurements. The systems and methods described herein can be applied to measure a number of different anatomical features (e.g., an organ, a tumor, a fluid region, a cyst, and / or an intraperitoneal hemorrhage), and cam assist in diagnosing conditions such as organ hypertrophy or atrophy.

The present disclosure relates to a composition for preventing or treating muscle disease, comprising CXCL14 as an active ingredient. According to the present disclosure, it was confirmed that CXCL14 increased muscle differentiation and synthesis, thereby increasing muscle mass. In addition, it was confirmed that in LPS-induced muscular atrophy or DEX-induced muscular dystrophy, CXCL14 inhibited muscle loss, increased the expression of muscle synthesis and differentiation factors, and inhibited the expression of muscle degradation proteins. In addition, it was confirmed that CXCL14 promoted muscle synthesis and differentiation and inhibited the muscle degradation even in vivo.

The invention discloses a multi-modal feature fusion prediction method and system for early screening of Alzheimer's disease, and belongs to the technical field of brain disease prediction. The method comprises the following steps: acquiring multi-dimensional data containing cognitive test scores, brain image scanning results and biomarker concentration levels from a patient record database, and performing standardization processing to obtain a multi-dimensional data set in a unified format; key feature vectors are extracted through a dimensionality reduction analysis method to capture the covariant relation between cognitive test scores and brain image changes; when the reduction range of the cognitive test score exceeds a preset threshold value and the brain image displays an atrophy sign, a classification model is constructed through an integrated learning method to preliminarily classify abnormal signals; and fusing the biomarker concentration level to obtain an abnormal signal vector. According to the method, the accuracy and efficiency of early screening of brain diseases such as Alzheimer's disease are remarkably improved through accurate evaluation of key parts of the human brain, such as hippocampus.

Methods for treating a subject with multiple system atrophy (MSA) using ampleloxetine or a pharma- ceutically acceptable salt thereof are disclosed. The disclosed methods include using ampleloxetine or a pharma- ceutically acceptable salt thereof to (i) treat symptoms of neurogenic orthostatic hypotension in a subject with MSA, (ii) reduce the magnitude of the decline in quality of life in a subject with MSA, and / or (iii) increase the level of norepinephrine in a subject with MSA.

The invention discloses a system for analyzing double-task cost and brain micro-injury of a Parkinson type multi-system atrophy patient, and relates to the technical field of medical diagnosis, and the system comprises a gait collection module which is used for collecting single-task and double-task gait data of a participant, and processing the gait data to obtain gait feature data of the participant; the gait analysis module is used for analyzing the difference of the participants in the single-task gait aspect and the double-task gait aspect according to the gait feature data and calculating the double-task cost; the nuclear magnetic resonance imaging module is used for collecting nuclear magnetic resonance imaging data of participants; the morphological analysis module is used for performing voxel-based morphological analysis on the nuclear magnetic resonance imaging data and analyzing the correlation between the double-task cost of the participant and the grey matter under the brain curtain; and the diffusion tensor imaging analysis module is used for performing diffusion tensor imaging analysis on the nuclear magnetic resonance imaging data and analyzing the correlation between the double-task cost of the participant and the white matter under the brain screen.

The present application relates to a kind of pharmaceutical composition for treating type 2 diabetes and its application.The pharmaceutical composition includes icariin, hydroxymethyl coumarin and cinnamaldehyde, by three-component synergistic effect, simultaneously act on insulin resistance, pancreatic beta cell apoptosis and systemic metabolic inflammation three type 2 diabetes core pathological links, auxiliary reduce serum lipid level, and reduce drug-related liver injury risk, good safety.Animal experiment results show that three-drug combination group can effectively reduce blood sugar (decrease about 50%), significantly improve islet structure atrophy, restore hepatocyte index arrangement, reduce glomerular hypertrophy, significantly reduce serum TG and CHOL level (P<0.05) and inflammatory factor IL-6 and TNF-alpha level (P<0.05), and avoid the hepatotoxicity risk (ALT / AST restores to close to normal level) of hydroxymethyl coumarin.The present application is composed of three kinds of natural monomers with clear structure, and has clear components and controllable quality, which provides a more optimal comprehensive treatment strategy for the treatment of type 2 diabetes and its complications.

The present invention relates to a compound of formula (I) wherein R1 is a hydrogen atom, halogen or -(C1-C2)alkyl, R2 is -halo(C1-C2)alkoxy, and R3 and R4 form together with N to which they are attached an optionally substituted 5-7 membered monocyclic heterocycloalkyl ring or an optionally substituted 8-11 membered bicyclic heterocycloalkyl ring. The present invention also relates to a medicament and a pharmaceutical composition comprising said compound of formula (I), as well as their therapeutic uses, in particular as inhibitor of NOD-like receptor protein 3 inflammasome for preventing and / or treating Parkinson's disease, frontotemporal Dementia, Multiple System Atrophy, Alzheimer's disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis or brain injury.

Provided is a method for treating musculoskeletal atrophy in patients suffering from a neurological or neuromuscular disease or disorder by combining testosterone replacement therapy with neuromuscular electrical stimulation of multiple muscle groups and, optionally, physical activity.